Saturday, May 23, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

1 In 10 Americans turn to social media for health information

Amid culture wars over masking, Covid-19 treatments, and vaccine mandates, many Americans are at a loss for who to trust when it comes to healthcare information.

With Facebook under new fire for putting profits over people based on a whistleblower’s testimony before Congress, it’s a wonder that anyone trusts social media platforms at all, especially in a healthcare context.

But according to new data released this week from PatientsLikeMe, an online patient community, 11% of Americans surveyed said they turn to social media when looking for reliable health information. Nearly one in ten (9%) also said they use social media to evaluate new treatment options and 7% seek information about medication side effects from social media.

Source: Forbes

https://www.forbes.com/sites/debgordon/2021/10/06/1-in-10-americans-turn-to-social-media-for-health-information-new-survey-shows/?sh=750cd1f3d934

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!